Research ArticleCardiovascular
Paradoxical Effects on Force Generation after Efficient β1-Adrenoceptor Knockdown in Reconstituted Heart Tissue
Christiane Neuber, Oliver J. Müller, Felix C. Hansen, Alexandra Eder, Anika Witten, Frank Rühle, Monika Stoll, Hugo A. Katus, Thomas Eschenhagen and Ali El-Armouche
Journal of Pharmacology and Experimental Therapeutics April 2014, 349 (1) 39-46; DOI: https://doi.org/10.1124/jpet.113.210898
Christiane Neuber
Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Germany, and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Germany (C.N., F.C.H., A.E., T.E.); Internal Medicine III, University Hospital Heidelberg, Germany, and DZHK (German Center for Cardiovascular Research), partner site Heidelberg, Germany (O.J.M, H.A.K.); Leibniz-Institute for Arteriosclerosis Research, University of Münster, Münster, Germany (A.W., F.R., M.S.); and Institute of Pharmacology, University Medical Center Göttingen, Göttingen, Germany, and DZHK (German Center for Cardiovascular Research), partner site Göttingen, Germany, and Department of Pharmacology, University of Technology Dresden, Dresden, Germany (A.E.-A.)
Oliver J. Müller
Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Germany, and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Germany (C.N., F.C.H., A.E., T.E.); Internal Medicine III, University Hospital Heidelberg, Germany, and DZHK (German Center for Cardiovascular Research), partner site Heidelberg, Germany (O.J.M, H.A.K.); Leibniz-Institute for Arteriosclerosis Research, University of Münster, Münster, Germany (A.W., F.R., M.S.); and Institute of Pharmacology, University Medical Center Göttingen, Göttingen, Germany, and DZHK (German Center for Cardiovascular Research), partner site Göttingen, Germany, and Department of Pharmacology, University of Technology Dresden, Dresden, Germany (A.E.-A.)
Felix C. Hansen
Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Germany, and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Germany (C.N., F.C.H., A.E., T.E.); Internal Medicine III, University Hospital Heidelberg, Germany, and DZHK (German Center for Cardiovascular Research), partner site Heidelberg, Germany (O.J.M, H.A.K.); Leibniz-Institute for Arteriosclerosis Research, University of Münster, Münster, Germany (A.W., F.R., M.S.); and Institute of Pharmacology, University Medical Center Göttingen, Göttingen, Germany, and DZHK (German Center for Cardiovascular Research), partner site Göttingen, Germany, and Department of Pharmacology, University of Technology Dresden, Dresden, Germany (A.E.-A.)
Alexandra Eder
Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Germany, and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Germany (C.N., F.C.H., A.E., T.E.); Internal Medicine III, University Hospital Heidelberg, Germany, and DZHK (German Center for Cardiovascular Research), partner site Heidelberg, Germany (O.J.M, H.A.K.); Leibniz-Institute for Arteriosclerosis Research, University of Münster, Münster, Germany (A.W., F.R., M.S.); and Institute of Pharmacology, University Medical Center Göttingen, Göttingen, Germany, and DZHK (German Center for Cardiovascular Research), partner site Göttingen, Germany, and Department of Pharmacology, University of Technology Dresden, Dresden, Germany (A.E.-A.)
Anika Witten
Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Germany, and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Germany (C.N., F.C.H., A.E., T.E.); Internal Medicine III, University Hospital Heidelberg, Germany, and DZHK (German Center for Cardiovascular Research), partner site Heidelberg, Germany (O.J.M, H.A.K.); Leibniz-Institute for Arteriosclerosis Research, University of Münster, Münster, Germany (A.W., F.R., M.S.); and Institute of Pharmacology, University Medical Center Göttingen, Göttingen, Germany, and DZHK (German Center for Cardiovascular Research), partner site Göttingen, Germany, and Department of Pharmacology, University of Technology Dresden, Dresden, Germany (A.E.-A.)
Frank Rühle
Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Germany, and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Germany (C.N., F.C.H., A.E., T.E.); Internal Medicine III, University Hospital Heidelberg, Germany, and DZHK (German Center for Cardiovascular Research), partner site Heidelberg, Germany (O.J.M, H.A.K.); Leibniz-Institute for Arteriosclerosis Research, University of Münster, Münster, Germany (A.W., F.R., M.S.); and Institute of Pharmacology, University Medical Center Göttingen, Göttingen, Germany, and DZHK (German Center for Cardiovascular Research), partner site Göttingen, Germany, and Department of Pharmacology, University of Technology Dresden, Dresden, Germany (A.E.-A.)
Monika Stoll
Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Germany, and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Germany (C.N., F.C.H., A.E., T.E.); Internal Medicine III, University Hospital Heidelberg, Germany, and DZHK (German Center for Cardiovascular Research), partner site Heidelberg, Germany (O.J.M, H.A.K.); Leibniz-Institute for Arteriosclerosis Research, University of Münster, Münster, Germany (A.W., F.R., M.S.); and Institute of Pharmacology, University Medical Center Göttingen, Göttingen, Germany, and DZHK (German Center for Cardiovascular Research), partner site Göttingen, Germany, and Department of Pharmacology, University of Technology Dresden, Dresden, Germany (A.E.-A.)
Hugo A. Katus
Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Germany, and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Germany (C.N., F.C.H., A.E., T.E.); Internal Medicine III, University Hospital Heidelberg, Germany, and DZHK (German Center for Cardiovascular Research), partner site Heidelberg, Germany (O.J.M, H.A.K.); Leibniz-Institute for Arteriosclerosis Research, University of Münster, Münster, Germany (A.W., F.R., M.S.); and Institute of Pharmacology, University Medical Center Göttingen, Göttingen, Germany, and DZHK (German Center for Cardiovascular Research), partner site Göttingen, Germany, and Department of Pharmacology, University of Technology Dresden, Dresden, Germany (A.E.-A.)
Thomas Eschenhagen
Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Germany, and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Germany (C.N., F.C.H., A.E., T.E.); Internal Medicine III, University Hospital Heidelberg, Germany, and DZHK (German Center for Cardiovascular Research), partner site Heidelberg, Germany (O.J.M, H.A.K.); Leibniz-Institute for Arteriosclerosis Research, University of Münster, Münster, Germany (A.W., F.R., M.S.); and Institute of Pharmacology, University Medical Center Göttingen, Göttingen, Germany, and DZHK (German Center for Cardiovascular Research), partner site Göttingen, Germany, and Department of Pharmacology, University of Technology Dresden, Dresden, Germany (A.E.-A.)
Ali El-Armouche
Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Germany, and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Germany (C.N., F.C.H., A.E., T.E.); Internal Medicine III, University Hospital Heidelberg, Germany, and DZHK (German Center for Cardiovascular Research), partner site Heidelberg, Germany (O.J.M, H.A.K.); Leibniz-Institute for Arteriosclerosis Research, University of Münster, Münster, Germany (A.W., F.R., M.S.); and Institute of Pharmacology, University Medical Center Göttingen, Göttingen, Germany, and DZHK (German Center for Cardiovascular Research), partner site Göttingen, Germany, and Department of Pharmacology, University of Technology Dresden, Dresden, Germany (A.E.-A.)
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleCardiovascular
β1-Adrenoceptor Knockdown in EHTs
Christiane Neuber, Oliver J. Müller, Felix C. Hansen, Alexandra Eder, Anika Witten, Frank Rühle, Monika Stoll, Hugo A. Katus, Thomas Eschenhagen and Ali El-Armouche
Journal of Pharmacology and Experimental Therapeutics April 1, 2014, 349 (1) 39-46; DOI: https://doi.org/10.1124/jpet.113.210898
Research ArticleCardiovascular
β1-Adrenoceptor Knockdown in EHTs
Christiane Neuber, Oliver J. Müller, Felix C. Hansen, Alexandra Eder, Anika Witten, Frank Rühle, Monika Stoll, Hugo A. Katus, Thomas Eschenhagen and Ali El-Armouche
Journal of Pharmacology and Experimental Therapeutics April 1, 2014, 349 (1) 39-46; DOI: https://doi.org/10.1124/jpet.113.210898
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement